Biotech and Equity Alternatives: A Good Place to Be

I think from a macro perspective, there's an interesting case to be made that biotech vis-a-vis other equity alternatives is a really interesting place to be. And what I think is a pretty discreet asset class within biotech, now you've got an opportunity where across all equity sectors, performance for the S&P,. most analysts have tagged it at something close to flat, maybe up 5% on the year. That's a pretty low bar, but if you can be a good stock picker in the current climate, you can clearly exceed it. So we will start to see a much more rapid pace of capital deployment as a function of just LP's requiring investors to start to ensure